Symbiotec Pharmalab Ltd
Symbiotec Pharmalab is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets with approvals from global regulatory authorities including US FDA and EU-GMP.
Overview
About the Company
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions. With over 30 years of industry experience, the company has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations. As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres. The company focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.
Company Details
📋 Objects of Issue (Use of Proceeds)
- › Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
- › General corporate purposes
✅ Strengths
- ✓ Global leadership in corticosteroid and steroidal hormone APIs
- ✓ Long-standing relationships with domestic and international customers
- ✓ Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record
- ✓ Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers
- ✓ Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings
- ✓ Operates an integrated business across APIs, CDMO services and complex injectables
- ✓ Has one of India's largest industrial-scale fermentation capacities with 700 KL capacity
- ✓ Backward integration reduces dependence on external sources for key intermediates
- ✓ Develops differentiated double-chamber injectable products using in-house API capabilities
- ✓ Long-term manufacturing agreements and strategic partnerships support future business growth
⚠️ Risks
- ! Almost all revenue comes from API products, making the business dependent on API demand
- ! A large share of revenue comes from a few key customers, and losing them could hurt the business
- ! The company depends on key suppliers for raw materials, and supply disruptions could affect operations
- ! The company faces intense competition in both the API and CDMO businesses
- ! Failure to meet repayment obligations or loan covenants could adversely affect the business and finances